ODAC Casts 11 to 0 Vote in Favor of Cilta-Cel in R/R Multiple Myeloma
ODAC voted on the risk/benefit ratio of cilta-cel vs standard of care for patients with lenalidomide-refractory multiple myeloma.
ODAC voted on the risk/benefit ratio of cilta-cel vs standard of care for patients with lenalidomide-refractory multiple myeloma.
Abstract. First-generation KRAS G12C inhibitors, such as sotorasib and adagrasib, are limited by the depth and duration of clinical responses. One potential explanation for their…
The Latest in Oncology delivered weekly to your inbox, a simple click and you are set to go!
Crowdsourcing 5 clinically relevant questions for 5 pragmatic trials
Mesenchymal-epithelial transition factor (MET) pathway dysregulation may occur through various mechanisms including MET overexpression, MET gene amplification, or MET exon 14 skipping (METex14) mutations [1–3].…
Annual mask mandates during respiratory virus season are an insult to evidence based medicine
Hospital-associated venous thromboembolism (HA-VTE) remains a major public health issue, affecting an estimated 10 million patients per year.1 The first step in prevention of HA-VTE…
The Royal College of Surgeons expresses alarm over the practice at Walsall Manor.
This cohort study prospectively validates the simplified Geneva score, a risk assessment model for venous thromboembolism (VTE), and compares its performance with that of previously…
Open access journal of the Ferrata-Storti Foundation, a non-profit organization Open access journal of the Ferrata-Storti Foundation, a non-profit organization Department of Children and Adolescents…
Malmö hat einen Ruf als Hochburg von Kriminalität, Krawall und Judenhass. Der ESC sollte das Image der Stadt aufwerten, doch nun wühlt die Gaza-Frage alle…